Exon 2 was replaced with a modified one in which a point mutation results in the amino acid substitution of proline for alanine at position 30 (A30P), mimicking a mutation found in some Parkinson's disease patients. Cre-mediated recombination removed the floxed neomycin resistance cassette inserted between exon 1a and exon 1b.